ICCM

IceCure Medical Ltd. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website icecure-medical.com
Employees(FY) 65
ISIN IL0011224156

Performance

-1.68%

1W

-6.4%

1M

-15.22%

3M

+51.95%

6M

+9.35%

YTD

-10.69%

1Y

Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Advanced Technical Analysis

Technical Analysis of ICCM 2024-05-03

Overview:

In analyzing the technical indicators for ICCM stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and recommendations for pot...

See more ...

Recent News & Updates

2024-05-06 20:30
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense, Adding to Continued Positive Data Published Globally(Prnewswire)
2024-04-29 22:30
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response(Prnewswire)
2024-04-17 23:07
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA(Zacks)
2024-04-14 20:35
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer(Prnewswire)
2024-04-03 21:28
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript(Yahoo Finance)
2024-04-03 21:28
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-04-03 00:52
ICCM Stock Earnings: Icecure Medical Meets EPS, Beats Revenue for Q4 2023(Investorplace)
2024-04-02 20:30
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance(Prnewswire)
2024-04-01 20:30
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes(Prnewswire)
2024-03-26 20:30
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024(Prnewswire)
2024-03-18 20:30
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy(Prnewswire)
2024-03-11 20:30
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes(Prnewswire)
2024-03-06 19:30
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference(Prnewswire)
2024-03-03 19:30
IceCure's ProSense a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024(Prnewswire)
2024-02-26 19:00
Fourth BRIIT Conference in India Features IceCure's ProSense in Breast Cancer Imaging & Interventions Workshop(Prnewswire)
2024-02-25 19:00
Study Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer(Prnewswire)
2024-02-14 19:00
IceCure's ProSense to be Featured at Two Upcoming Medical Conferences in Japan(Prnewswire)
2024-01-29 19:00
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense for Early-Stage Breast Cancer(Prnewswire)
2024-01-28 19:00
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class(Prnewswire)
2024-01-15 19:00
IceCure Medical's ProSense Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation(Prnewswire)
2024-01-12 03:05
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule(Globenewswire)
2024-01-09 19:00
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results(Prnewswire)
2024-01-02 19:00
New Study Reports IceCure's ProSense Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response(Prnewswire)
2023-12-12 19:00
Study Using IceCure's ProSense Finds: 'Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients'(Prnewswire)
2023-11-28 19:00
IceCure's ProSense Deepens Regulatory Approval in India(Prnewswire)
2023-11-28 00:41
5 Investors Betting Big on IceCure Medical (ICCM) Stock(Investorplace)
2023-11-27 19:00
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate(Prnewswire)
2023-11-14 20:15
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates(Yahoo Finance)
2023-11-14 19:00
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights(Prnewswire)
2023-11-14 18:30
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer(Prnewswire)

Page 1 of 4

previousnext